The University of Texas MD Anderson Cancer Center and Pfizer Inc. today announced that they have entered into a clinical collaboration to study novel combinations of three Pfizer investigational immuno-oncology therapies and other Pfizer agents in the treatment of various solid tumors and hematologic malignancies. “This alliance aims to define patients with solid tumors who may …
Original Article: MD Anderson and Pfizer Collaborate to Evaluate Immuno-Oncology Combinations in Blood Cancers and Solid Tumors
NEXT ARTICLE